What are the new Scientific and industrial fundamentals for the future of life sciences?

• Changing paradigm for cancer (Maël MONTEVIL, Theoretical biology, CNRS & ENS & Ana Soto, Tufts University School of Medicine, Boston) 

[More content to come]

• New regulatory science paradigms powered by data & benefiting patients (Eddie REILLY, Chief Regulatory Officer, Global Head Regulatory Affairs, Sanofi)

A series of new and advanced digital technologies (wearables, digital biomarkers, cloud computing, federated ledgers, cognitive computing/machine learning, etc.) has reached such level of maturity that it is now realistic to envision opportunities in the regulated Pharmaceutical healthcare space that can reshape the regulatory process of the future representing true paradigm shifts.

A paradigm shift powered by data that not only helps keep the patients as the key driver of the process but it further empowers them. We’ll explore three such opportunities/realities in the regulated pharmaceutical space relating to new ways to conduct clinical trials using novel approaches and sources of data (DCTs, RWE/ECA), new ways technology is facilitating remote inspections and the opportunities technology brings for high quality and efficient regulatory review and decision-making.